← Leaderboards
Jacob Houghton
Sloan-Kettering Inst Can Research
$1,773,649
Attributed
$1,969,425
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $818.8K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,969,425 · 4
By mechanism
R37$817,435 · 1
R21$638,000 · 1
R42$391,553 · 1
F32$122,437 · 1
Top collaborators
- Michael King Schultz1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- John Thomas Poirier$4,490,380
- Lisa Bodei$1,419,480
- Simone Krebs$3,266,625
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureRadiolabeledTumorBiodistributionChelating AgentsImageRadioisotopesMouse ModelLabelAntibodiesDrug KineticsLeadUptakeIn VivoBindingBaseLengthMalignant NeoplasmsDosimetryMonoclonal AntibodiesImaging PlatformClinical PracticeInjectionsChemistry
Grant awards (9)
Radiotheranostic host:guest pretargeting with Pb-203 and Pb-212$390,201
R37 · FY2025 · CA · contact PI
Radiotheranostic host:guest pretargeting with Pb-203 and Pb-212$427,234
R37 · FY2024 · CA · contact PI
Antibody-based prertargeted alpha particle therapy for ovarian cancer$391,553
R42 · FY2024 · CA
Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform$199,375
R21 · FY2022 · EB · contact PI
Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform$199,375
R21 · FY2021 · EB · contact PI
Development and Validation of a Robust and Modular Host: Guest-based Pretargeting Platform$239,250
R21 · FY2020 · EB · contact PI
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer$16,713
F32 · FY2016 · CA · contact PI
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer$54,194
F32 · FY2015 · CA · contact PI
Developing an Anti-sialyl-Lewisa Diabody for ImmunoPET Imaging of Pancreas Cancer$51,530
F32 · FY2014 · CA · contact PI